HBOT Conversations:
Robert Beckman & NBIRR Study
Robert Beckman, Ph.D., Founder of the TreatNow Coalition in Arlington, Virginia, discusses the National Brain Injury Rescue Rehabilitation study focused on the use of Hyperbaric Oxygen Therapy for brain injuries. Beckman has a passion for data and helping veterans, which is what ultimately got him first involved in Hyperbaric Oxygen Therapy back in 2008. He was one of many, participating with an elite group of doctors and HBOT experts, who organized and oversaw the results of NBIRR, a multi-center HBOT trial for mild traumatic brain injury with post-concussive symptoms.
The TreatNow Coalition’s Mission is to Stop service member suicides by identifying and treating veterans and others suffering from brain wounds, TBI, PTSD, and Concussion.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with guest, Robert Beckman, founder of Treatnow.org, who was instrumental in the compilation and release of The National Brain Injury Rescue and Rehabilitation Study – a multicenter observational study of hyperbaric oxygen for mild traumatic brain injury with post-concussive symptoms.
It took over a decade for that study to be completed and published. Once it was, it not only opened a door for veterans and others who were looking for a way to heal from head trauma, the NBIRR study ignited other studies to start, focusing solely on the safety & efficacy of Hyperbaric Oxygen Therapy for brain injuries.
Beckman discusses some of the challenges he has witnessed over the years, including the Army declaring that HBOT does not work. After combing through the data, Beckman states that their analysis is rooted in a “lie” about the sham they used in their study; everyone got better. This starts an in-depth conversation between di Girolamo and Beckman about the frustration of the government so easily dismissing HBOT, inflammation linked to PTSD, the stigma of PTSD being a personal and not a physical problem, the disappointment that most veterans don’t even know HBOT exists, and why more is not being done to heal our veterans from these invisible injuries of war.
Beckman proudly states that what started as nine clinics to treat veterans under the NBIRR study, has grown to about 135 clinics across the country that specialize in treating veterans with HBOT for free or reduced rates. Additionally, there are now a combined 12,500-plus success stories from these 135 clinics of individuals with TBI, PTSD, and mTBI who have completed 40 treatments/dives.
Beckman gives surgical statistics relating to HBOT and explains that by pre-oxygenating and post-oxygenating via hyperbaric chambers, patients can benefit from a 30-40% faster healing rate. He points out that countless professional athletes are now using hyperbaric oxygen therapy for faster recuperation to treat pain, injuries, and inflammation; and hyperbarics is being used all over the world right now for successfully treating COVID long-haulers. He states that COVID long-haulers are hypoxic suffering patients, and data exists that military personnel who have experienced the blow of an IUD are suffering in much of the same manner – it’s that lack of oxygen to the brain and all parts of the suffering body that HBOT helps.
di Girolamo asks the question so many of us are curious about, “If HBOT obviously works, why isn’t the military admitting to this? Why aren’t we using it more?” Beckman suggests we read this particular blog on his website that sheds much light on the subject, The Obvious Question: If HBOT works, why aren’t we using it?
Beckman reminds di Girolamo – and all of us – that this is a marathon. Yes, they’ve made great strides over the past two decades in education and research for hyperbaric oxygen therapy, but they still have a way to go. He continues to be optimistic that one day we’ll all witness our shared goal of eliminating the suicide epidemic by utilizing HBOT to thoroughly heal brain injuries.
Guest
Robert L. Beckman, Ph.D.
Dr. Beckman has been building knowledge management systems most of his professional career, primarily in the Intelligence Community and DOD. He is currently helping to run the Clinical Trial researching TBI and PTSD in brain-injured wounded warriors. He is responsible for sustaining the national network of hyperbaric clinics as well as improving the technology platform for data collection and analysis. He is a former USAF KC-135 pilot and a Vietnam Veteran.
TreatNow.org
(571) 549-4258
beckmanr88@gmail.com
Contact TreatNow.org
https://treatnow.org/
Subscribe Now, It’s Free !
Recent HBOT News
Healing of spongiosus-cutaneous fistula with Hyperbaric Oxygen Therapy (HBOT): a case report.
Abstract: We present a case of a spongiosus-cutaneous fistula in a 39-year-old man with recurrent episodes of cutaneous abscess in dorsal middle third penis (5 - 3 cm) treated with Hyperbaric Oxygen Therapy (HBOT). After emptying nodular abscess, the patient was...
Clinical Trial – Caudal Block,Saddle Block, Anorectal Surgery
Anorectal surgery includes pilonidal sinus, hemorrhoidectomy, anal fissure, and anal fistula
operations. Various surgical and anesthetic techniques have been used to increase the level
of analgesia in perioperative period and decrease the length of stay in the hospital. In this
study, investigators investigate the effects of routinely applied anesthesia techniques
during anorectal surgery, caudal block and saddle block, on patients’ perioperative
hemodynamic values, sensory and motor block levels, and postoperative pain scores.
Clinical Trial – Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with recurrent
mucosal inflammation. Clinically, the disease is characterized by bloody diarrhea, abdominal
pain, and constitutional symptoms such as fever and weight loss. Treatment strategies vary
based on disease activity and target various aspects of the inflammatory cascade. Options
include: anti-inflammatory drugs (mesalamine), immunosuppressive or modulatory medications
(corticosteroids, thiopurines, cyclosporine) and biologic agents (Anti-TNF). Disease severity
can be wide ranging, and nearly 25% of UC patients are hospitalized for acute severe disease.
Of these patients, 30% will undergo colectomy after the acute episode, a quarter of which
will experience post-operative complications. Although there has been great progress in
treatment of UC over the past decade, even with the anti-TNF agent infliximab, the one-year
remission rate for patients not responding to conservative management is barely 20%.
Furthermore, corticosteroids have significant long-term consequences and immune suppressive
drugs such as 6-mercaptopurine, azathioprine and infliximab have been associated with serious
adverse events including life-threatening infections and lymphomas. With growing evidence
that the pathogenesis of UC is multi-factorial and involves a complex interaction of genetic
and environmental factors, newer treatment modalities are being evaluated to target the
mucosal immune response and mucosal inflammatory regulatory system.
Hyperbaric oxygen offers a promising new treatment option since it targets both tissue
hypoxia and inflammation. Recent small scales studies evaluating the impact of hyperbaric
oxygen treatment in acute ulcerative colitis flares demonstrated improved outcomes. The
mechanisms underlying the improvement are not known. In this study, we will treat ulcerative
colitis flares with hyperbaric oxygen and measure changes in both markers of tissue hypoxia
and inflammation. We hypothesize that hyperbaric oxygen will (a) improve outcomes, and (b)
show reductions in markers of both tissue hypoxia and inflammation.